GLP-1 obesity drugs in focus as Medicare pilot launches and Swiss biotech research emerges

The U.S. Medicare program will begin a pilot in July that offers GLP‑1 receptor agonists for weight loss at a flat $50 monthly copayment, prompting expectations of a surge in new prescriptions. A Business Group on Health survey found that nearly 80 % of employers say GLP‑1 drugs are raising health‑care costs, and some may drop coverage next year. The American College of Physicians released new clinical guidelines on medication‑assisted weight management for adults.

Swiss biotech firm MetaShape Pharma presented early animal data indicating its candidate MS 001 can augment GLP‑1 therapy by preserving muscle mass, enhancing fat loss, and increasing energy expenditure without further reducing food intake. The findings suggest a potential shift toward obesity treatments that improve body composition rather than solely focusing on total weight loss.